DEFA14A filed Nov 13, 2026 at 20:56 ET
CorMedix reported Q3 2026 consolidated revenue of $54.5 million (down 48% YoY from $104.3M due to the DefenCath post-TDAPA transition) and a GAAP net loss of $14.7 million vs. net income of $108.6M in Q3 2025. The company reaffirmed FY2026 revenue guidance of $325M-$345M and narrowed adjusted EBITDA guidance to $130M-$140M. Management deferred 2027 DefenCath revenue guidance due to CMS's new quarterly add-on methodology, while noting the Heron asset acquisition (expected to close Q1 2027) should be immediately accretive.